Who can get flu antivirals in Europe, and when do they work?
Flu antivirals are prescription-only in every EU country and must start within 48 hours of the first symptom. They shorten flu by about a day and cut chest complications in people at higher risk. Doctors reserve them for people aged 65 or over, pregnant women, the chronically ill and anyone severely ill.
Are flu antivirals sold over the counter in Europe?
No. Flu antivirals are prescription-only in every EU country, and no pharmacy can sell them over the counter. ECDC puts it plainly: like antibiotics, antivirals require a medical prescription and are not over-the-counter drugs. The rule holds in all twelve countries where our doctors see patients.
A pharmacist can advise on symptom relief, but a doctor must decide on the antiviral. Antibiotics do not work for viral infections such as flu. Our guide to antibiotics over the counter in Europe explains which countries sell them without a prescription, and why that does not help with flu.
The two main products hold a single EU-wide marketing authorisation, so the age limits and the 48-hour window are the same in every member state. National practice differs in how strictly the drugs are kept for people at higher risk. If you need an in-person doctor while abroad, our guide to urgent care in Europe explains where to go.
Do flu antivirals work?
Yes, modestly. Flu antivirals shorten the illness by about one day and lower the chance of a chest complication, provided treatment starts early. The licensing trials of the standard capsule antiviral measured this in adults and adolescents treated early. They were ill for a median of 4.2 days, against 5.2 days on placebo.
Lower respiratory tract complications treated with antibiotics, mainly bronchitis, fell from 12.7% to 8.6%. In people aged 65 and over, and in those with chronic heart or lung disease, the illness itself was not significantly shorter. Fever, though, ended a day earlier.
Among influenza-positive older people, chest complications treated with antibiotics fell from 19% to 12%. That is why European guidance aims the drugs at people at risk of complications. Our guide to pneumonia after flu covers its warning signs.
The newer single-dose tablet cut the median time to symptom relief in otherwise healthy adults and adolescents from 80.2 hours to 53.7 hours. In people at higher risk of complications, symptoms improved after a median of 73.2 hours against 102.3 hours on placebo.
Most people recover from flu on their own, and ECDC notes that antivirals are usually not recommended for otherwise healthy adults with ordinary influenza. No antiviral replaces the vaccine: the EU product information states that it is not a substitute for influenza vaccination.
When do flu antivirals need to start?
Treatment must start within 48 hours of the first symptom, and the earlier the better. The clock starts at your first symptom, not at the day you felt worst or saw a doctor. If the first symptom began on Monday evening, the window closes on Wednesday evening.
The EU product information for the capsule antiviral says efficacy has been demonstrated when treatment starts within two days of first onset of symptoms. The single-dose tablet carries the same instruction: a single dose taken as soon as possible within 48 hours of symptom onset.
Flu symptoms come on very quickly, with a sudden high temperature, body aches and exhaustion, so most people can name the day. A positive test isn't part of the rule: NICE's criteria focus on an influenza-like illness while national surveillance shows flu circulating. Our tracker shows flu levels across Europe this week, country by country.
Who should get flu antivirals in Europe?
People at higher risk of complications, and anyone with severe or worsening flu. At-risk groups are consistent across European guidelines, and a healthy adult with ordinary flu usually does not qualify.
- Age 65 or over.
- Pregnancy, including the two weeks after giving birth.
- Chronic lung disease, including asthma and COPD, and chronic heart disease.
- Long-term kidney or liver disease.
- Diabetes and chronic neurological conditions.
- A weakened immune system, from disease or from treatment such as chemotherapy.
- Severe obesity, meaning a body mass index of 40 or more.
- Anyone, in any group, who is severely ill, getting worse or needs hospital care.
NICE's technology appraisal for treating flu sets three conditions that have to be met together. National surveillance shows influenza A or B circulating, the person is in an at-risk group, and treatment can start within 48 hours.
UK Health Security Agency guidance updated on 23 October 2026 adds pregnancy and severe obesity to the at-risk list. It also states that a previously healthy adult with non-severe flu does not need antiviral treatment.
ECDC names the same groups for EU countries: people with chronic disease, pregnant women, immunocompromised persons and those aged 65 and above.
Ireland's HPSC guidance (version 4.1, 29 September 2026) does not recommend antiviral treatment for non-severe flu, even in at-risk groups. It asks GPs to treat only severe illness, and only once HPSC has issued an alert that flu is widely circulating.
Children are outside our service. A child in a risk group, or one struggling to breathe, unusually drowsy or not drinking, needs local paediatric care, and 112 for severe breathing difficulty.
What our doctors prescribe for flu, and when
Our doctors prescribe a flu antiviral when the criteria above are met: an at-risk patient, flu circulating, and an early start. Three antivirals are authorised for flu in the EU, and one of them does most of the work. This winter's dominant strain remains sensitive to all three in nearly every virus tested.
The three medicines
Oseltamivir (Tamiflu, and generics such as Ebilfumin) is the first-line choice in European guidance. It comes as capsules, with a liquid for children, and the licensed treatment course is five days for most patients.
Baloxavir marboxil (Xofluza) is a single dose by mouth, taken as soon as possible within 48 hours of the first symptom. It is authorised for uncomplicated flu and for prevention after close contact. It is not on sale in every EU country: Ireland's HPSC notes that it is not currently marketed there.
UK guidance reserves baloxavir for patients who cannot take oseltamivir or inhaled zanamivir, or where resistance to those drugs is known. Zanamivir (Relenza) is inhaled through a device; an intravenous form (Dectova) also exists. UK guidance keeps inhaled zanamivir for patients who do not respond to oseltamivir, cannot keep it down, or have a strain with possible oseltamivir resistance.
Resistance this winter
This winter's dominant virus so far is A(H1N1)pdm09, and our guide to this winter's flu strains follows it week by week. The CDC tested 537 viruses collected since 24 May 2026 (FluView week 42, published 30 October 2026). Of these, 8 (1.5%), all A(H1N1)pdm09, showed reduced inhibition by oseltamivir. None showed reduced susceptibility to zanamivir, peramivir or baloxavir.
Of the A(H1N1)pdm09 viruses characterised, 99.7% belonged to subclade D.3.1.1. ECDC notes that resistant viruses that spread to others are very rare.
Whatever the antiviral decision, symptom relief is the same: our doctors suggest paracetamol or ibuprofen for fever and aches, plenty of fluids, and rest.
Are flu antivirals in short supply in Europe?
Mostly no. Our shortage tracker reads ten national and EU medicines registers every morning. As of 2 November 2026 it showed active availability issues for the brand-name capsules in 1 of the 10 tracked registers, Spain's AEMPS. The current shortage status for flu antivirals is refreshed there daily.
Spain's shortage covers one capsule strength of the brand (since 7 January 2024) and the generic capsules (since 22 June 2026), with same-substance alternatives available. Austria's BASG lists the children's liquid as limited since 12 December 2025 because of a manufacturing delay.
| Country we serve | Register | Status on 2 November 2026 |
|---|---|---|
| Austria | BASG | Capsules: no current report; children's liquid limited until 30 November 2026 |
| France | ANSM | No current report |
| Germany | BfArM | No current report |
| Greece | National register | No current report |
| Ireland | HPRA | No current report; single-dose tablet not marketed |
| Italy | National register | No current report |
| Spain | AEMPS CIMA | Brand capsules short since 7 January 2024; generic short since 22 June 2026 |
| Denmark, Luxembourg, Netherlands, Portugal, Romania | Not tracked | Ask the pharmacy to check stock |
A missing report means no flagged problem, not guaranteed stock; if one pharmacy is out, try another.
What are the side effects of flu antivirals?
Nausea and vomiting are the commonest problems with the standard capsule antiviral, and they usually pass quickly. In the treatment studies most episodes happened once, on the first or second day, and settled within one to two days. Headache is also very common.
Rarely, serious allergic reactions, severe skin reactions, liver problems and neuropsychiatric events have been reported since marketing. A rash, facial swelling or a sudden change in behaviour therefore needs medical advice straight away. With the single-dose tablet, diarrhoea and vomiting are common and hives are uncommon. Allergic reactions including anaphylaxis have been reported at a frequency that is not known.
Are flu antivirals safe in pregnancy?
Pregnancy is a reason to treat, not a reason to hold back. Pregnant women are at increased risk of being admitted to hospital with flu. UK Health Security Agency guidance states that antivirals are recommended in pregnancy, with the standard capsule antiviral first line.
The EU product information says a large amount of data from post-marketing reports and observational studies is available. It adds that the use of the capsule antiviral may be considered during pregnancy if necessary. In breastfeeding, it may be considered where there are clear potential benefits to the mother.
For the single-dose tablet there are no or limited data in pregnant women. The product information says it is preferable to avoid it, and UK guidance does not currently recommend it in pregnancy.
What if you missed the 48-hour window?
Missing the 48-hour mark does not change the plan for most adults. Treat the symptoms, rest, and watch for the warning signs in the next section. For an otherwise healthy adult with ordinary flu, an antiviral started on day three adds little.
ECDC says that in severe flu, in hospital patients and in high-risk people, the benefits of starting late may outweigh the reduced efficacy. UK Health Security Agency guidance adds that treatment started beyond 48 hours is off-label. It may still be valuable up to five days from symptom onset, mainly in critically ill patients.
For everyone else, the practical steps are in our guide to recovering from flu faster. They are:
- Fluids until your urine is light yellow or clear.
- Sleep and rest.
- Fever and pain relief from the pharmacy.
- Stay at home while you have a high temperature.
A fever that pharmacy medicines will not settle is covered on our fever consultation page. Over Christmas and New Year, our guide to duty pharmacies over the holidays shows which pharmacy is open.
When to see a doctor
Call 112 anywhere in the EU for the emergency signs of flu. These are sudden chest pain, severe difficulty breathing (gasping, choking or not able to get words out), and coughing up blood.
See a doctor without waiting if you have flu symptoms and are aged 65 or over, pregnant or recently given birth, or have a long-term condition. The same applies with a weakened immune system, for example from chemotherapy or HIV. Feeling very unwell or short of breath, or no improvement after seven days, also means a doctor.
In countries we do not cover, such as Belgium, Switzerland and Croatia, use the local GP or out-of-hours service, and 112 for emergencies.
What a video doctor can do
You can see one of our EU-registered doctors over video usually within 15 minutes, daily 7am–11pm CET. The service is for adults in Austria, Denmark, France, Germany, Greece, Ireland, Italy, Luxembourg, the Netherlands, Portugal, Romania and Spain.
The doctor establishes when the first symptom appeared, which fixes the 48-hour clock. The doctor asks about the risk factors listed above, including pregnancy, and checks for the warning signs that need in-person care. Other medicines, allergies and kidney function come up too, because kidney function affects antiviral dosing.
If the criteria are met, the doctor can issue a prescription for an antiviral, sent to a pharmacy you choose. If they are not met, the doctor explains why and what to watch for.
A doctor cannot listen to your chest, measure your oxygen level, swab you or arrange an X-ray over video. So breathing difficulty, chest pain or dehydration need in-person assessment, and 112 if severe. Our page on flu assessment over video lists what else the visit covers.
How to prevent flu: the vaccine comes first
Vaccination is the most effective form of flu prevention, and no antiviral replaces it. The WHO recommends a yearly vaccine for pregnant women, children aged six months to five years, people over 65, people with chronic conditions and health workers. Mobi Doctor does not vaccinate; pharmacies and GP practices in the countries we serve run autumn campaigns.
Our guide to getting a flu jab in Europe lists the options in each of the 12 countries.
Antivirals can also prevent flu after close contact with a case, if started within two days of the contact. ECDC describes this as case-by-case use: people at risk after household exposure, and everyone at risk during a proven outbreak in a care home or hospital ward.
How long are you contagious with flu?
About a week. Adults carry the virus from about one day before symptoms start until five to seven days after. Shedding lasts longer in young children, older people and anyone with a weakened immune system. You are most likely to pass flu on in the first five days.
Antiviral or not, the advice is to stay at home and avoid contact with other people while you have a high temperature. Our calculator for how long flu is contagious turns your first-symptom date into a day-by-day answer. If you are in a risk group, that first day is the day to see a doctor.
Sources
- EMA: product information (SmPC) for the oral capsule flu antiviral, EPAR, EU product information (last renewal 22 May 2012; current EPAR document) (accessed 2 November 2026)
- EMA: product information (SmPC) for the single-dose tablet flu antiviral, EPAR, EU product information (latest renewal 17 November 2025) (accessed 2 November 2026)
- NICE TA168: antivirals for the treatment of influenza, section 1 Guidance (accessed 2 November 2026)
- ECDC: Antiviral treatment of influenza (seasonal influenza, prevention and control; page last updated 25 May 2023) (accessed 2 November 2026)
- ECDC: Factsheet about seasonal influenza (page last updated 12 April 2022) (accessed 2 November 2026)
- CDC: FluView weekly US influenza surveillance report, week 42 (week ending 24 October 2026; published 30 October 2026) (accessed 2 November 2026)
- UK Health Security Agency: Guidance on use of antiviral agents for the treatment and prophylaxis of seasonal influenza (updated 23 October 2026) (accessed 2 November 2026)
- NHS: Flu (page last reviewed 3 February 2026) (accessed 2 November 2026)
- WHO: Influenza (seasonal) fact sheet (28 February 2025) (accessed 2 November 2026)
- HSE Health Protection Surveillance Centre (Ireland): Guidance on the use of antiviral agents for the treatment and chemoprophylaxis of influenza, version 4.1 (29 September 2026) (accessed 2 November 2026)
Written by the Mobi Doctor Medical Team. Medical review by Dr Chrysoula Liakou, MD, PhD: pending.